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Background: A microemulsion is an effective formulation for improving the oral   bioavailability 
of poorly soluble drugs. In this paper, a water-in-oil (w/o) microemulsion was investigated 
as a system for enhancing the oral bioavailability of Biopharmaceutic Classification System 
(BCS) III drugs.
Methods: The microemulsion formulation was optimized using a pseudoternary phase 
  diagram, comprising propylene glycol dicaprylocaprate (PG), Cremophor® RH40, and water 
(30/46/24 w/w).
Results: The microemulsion increased the oral bioavailability of hydroxysafflor yellow 
A which was highly water-soluble but very poorly permeable. The relative bioavailability of 
hydroxysafflor yellow A microemulsion was about 1937% compared with a control solution in 
bile duct-nonligated rats. However, the microemulsion showed lower enhanced absorption ability 
in bile duct-ligated rats, and the relative bioavailability was only 181%. In vitro experiments 
were further employed to study the mechanism of the enhanced effect of the microemulsion. 
In vitro lipolysis showed that the microemulsion was digested very quickly by pancreatic lipase. 
About 60% of the microemulsion was digested within 1 hour. Furthermore, the particle size of 
the microemulsion after digestion was very small (53.3 nm) and the digested microemulsion had 
high physical stability. An everted gut sac model demonstrated that cumulative transport of the 
digested microemulsion was significantly higher than that of the diluted microemulsion.
Conclusion: These results suggested that digestion of the microemulsion by pancreatic lipase 
plays an important role in enhancing oral bioavailability of water-soluble drugs.
Keywords: propylene glycol dicaprylocaprate, microemulsion, hydroxysafflor yellow A, 
bioavailability, lipolysis
Introduction
Lipid-based formulations have been widely used as oral delivery systems for poorly 
soluble drugs, including microemulsions, oil suspensions, and self-emulsifying 
systems.1–3 Oral lipid-based formulations have been marketed for over two decades, 
and presently comprise an estimated 2%–4% of commercially available drug products, 
according to a survey in three markets worldwide.4 Lipid-based formulations can 
increase the bioavailability of poorly soluble drugs. The mechanisms of absorption 
enhancement are very complicated, involving improved solubility of drug molecules, 
formation of mixed micelles, opening of tight junctions, and improved lymphatic 
delivery.5,6   Microemulsions also have the potential to increase the permeability of 
hydrophilic   peptides and proteins across the intestinal mucosa, thus enhancing their 
bioavailability.7,8 One of the proposed mechanisms involves enhancer-induced structural International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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and fluidity changes in the mucosal membrane.9 However, 
there are few reports on the enhancing effect of water-in-oil 
(w/o) microemulsions on Biopharmaceutics Classification 
System (BCS) III low molecular weight drugs. This study 
was undertaken to confirm this effect, using hydroxysafflor 
yellow A (HSYA) as a model drug.
HSYA is extracted from the flower of the safflower plant, 
Carthamus tinctorius L. HSYA is the active ingredient of 
the safflower plant, and has been demonstrated to antagonize 
platelet-activating factor receptor binding, and thus is used 
to treat several ischemic diseases, including myocardial isch-
emia, cerebral ischemia, coronary heart disease, and cerebral 
thrombosis.10–12 According to recent studies, HSYA is a 
hydrophilic drug with low oral bioavailability, belonging to the 
BCS III class of drugs.13 Our previous studies have suggested 
that medium chain triglycerides, and chuanxiong volatile oil14 
could increase the bioavailability of HSYA. However, the 
solubility of HSYA in oil is very low, so the compound must 
be prepared as a phytosome for increasing its solubility in oil. 
w/o microemulsion can dissolve water-soluble molecules in 
the inner phase, so may be the optimal formulation for HSYA. 
However, in this study, propylene glycol dicaprylocaprate 
(PG) was selected as the oil phase rather than medium chain 
triglycerides and chuanxiong volatile oil, because PG can 
form a more stable w/o microemulsion, and the maximum 
water phase volume in this w/o microemulsion system is 
larger than the microemulsion formed by the other two oils. 
This study was undertaken to investigate the enhancing effect 
and mechanism of intestinal absorption for HSYA by using 
PG as the oil phase for the microemulsion.
Materials and methods
reagents and chemicals
PG (Milgyol® 840) was kindly gifted by Sasol Chemical 
Co Ltd (Guangzhou, China). HSYA (84.2% purity) was 
purchased from Changsha Keluoma Pharmaceutical Co Ltd 
(Changsha, China). Porcine pancreatic lipase was obtained 
from the Shanghai Chemical Reagent Co Ltd (Shanghai, 
China). Riboflavin (98.0% purity) was purchased from 
Sigma-Aldrich Chemical Company (Shanghai, China). The 
lactate dehydrogenase diagnostic cassette used is a product 
of the Nanjing Jiancheng Bioengineering Institute (Nanjing, 
China). All other chemicals were of analytical grade and 
used as received.
Animals
Male Wistar rats (200–240 g), obtained from the Animal Cen-
ter of the China Pharmaceutical University, were   maintained 
under uniform experimental conditions   (temperature 
25 ± 2°C, humidity 60 ± 5%, on a 12-hour dark/light cycle) 
for 1 week prior to experiments. They were fed with a stan-
dard laboratory diet. All rats were fasted overnight before 
the experiment, with water ad libitum. All the animal experi-
ments followed the recommendations of the Regulations 
for the Administration of Affairs Concerning Experimental 
Animals and were approved by the ethics committee of the 
China Pharmaceutical University.
Preparation of hsYA w/o microemulsion
The pseudoternary phase diagram was constructed to form 
the microemulsion.15 Cremophor RH40 (surfactant) and 
ethanol (cosurfactant) were mixed in a vial at room tempera-
ture followed by the addition of PG (oil phase), and then the 
mixture was blended for 5 minutes until they had completely 
mixed. The HSYA solution was then added to the mixture 
and stirred for 3 minutes until a clear and transparent w/o 
microemulsion was obtained.
In vitro properties of hsYA  
w/o microemulsion
The electrical conductivity (σ) of the prepared microemul-
sion was determined at ambient temperature by a DS-11C 
conductivity meter coupled with a platinum electrode (Leici 
Instrument Co, Shanghai, China). Deionized water and 
saline were used to calibrate the instrument. The dynamic 
viscosity (η) of the microemulsion was monitored using 
a rotational Brookfield DV-III viscometer (Brookfield 
  Engineering Laboratories, Middleboro, MA). For measur-
ing the particle size and zeta potential, the microemulsion 
was diluted   100-fold by artificial intestinal juices. The 
particle size and zeta potential of the diluted microemulsion 
were determined by a Zetasizer 3000 instrument (Malvern 
  Instruments,   Worcestershire, UK).
Oral bioavailability in bile duct-ligated 
and non-ligated rats
Eighteen rats were divided into three groups. After anesthesia 
with 15% urethane (1 mL/100 g), the first group (controls) 
underwent intraduodenal administration of HSYA solution 
12.5 mg/kg, the second group underwent intraduodenal 
administration of the microemulsion, and the third group 
underwent intraduodenal administration of the micro-
emulsion after ligation of the bile duct. Bile duct ligation 
was performed as described previously,16 and the midline 
abdominal incision required was covered by sterile gauze to 
maintain body temperature. In brief, under anesthesia, the International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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common bile duct was ligated with 3-0 silk and sectioned 
between the ligatures. The microemulsion was administered 
intraduodenally to the rats 2 hours after bile duct ligation, 
when all bile was depleted. The HSYA microemulsion dosage 
was 12.5 mg/kg. After administration, serial blood samples 
were collected at 10, 20, 30, 45, 60, 90, 120, 180, 300, and 
420 minutes. Each sample was immediately transferred 
to another heparinized tube and centrifuged at 5000 g for 
5 minutes. The plasma was transferred to another tube and 
stored at −20°C until analysis. For 100 µL of plasma, 50 µL 
of internal standard (IS) solution (riboflavin 10 µg/mL) and 
40 µL of 6% perchloric acid were added. Each sample was 
vortex-mixed for 2 minutes and centrifuged for 10 minutes at 
9000 g. A 50 µL aliquot of the supernatant was injected into 
the chromatography system. The pharmacokinetic parameters 
were calculated by statistical moment theory.
Microemulsion lipolysis in vitro
The lipolysis procedure was performed as described by 
Zangenberg et al,17,18 with some slight modification. In brief, 
4 g of microemulsion was added to 20 mL of digestive buffer 
containing bile salt 5 mM, phosphatidylcholine 1 mM, trizma 
maleate 2 mM, NaCl 150 mM, and CaCl2 20 mM. The solu-
tion was stirred gently and heated to 37°C. Fresh pancreatic 
lipase extract was prepared by adding porcine pancreatic 
lipase to distilled water and stirring for 15 minutes. The 
supernatant was collected after centrifugation. Enzymatic 
digestion was started by adding the fresh pancreatic lipase 
extract to the previously mixed solution (1000 IU/mL lipase). 
The experiment was performed under continuous agitation 
by magnetic stirring (100 rpm) and pH was maintained 
at 6.5 by titration with NaOH 0.05 M. After 30 minutes, 
4-bromobenzeneboronic acid solution was added to halt 
lipase activity immediately.19 Microemulsion particle size 
after digestion was measured by the Zetasizer 3000.
everted gut sac transport study
Four grams of microemulsion were diluted 20-fold with 
Tyrode’s solution. Another 4 g of microemulsion was first 
digested by pancreatic lipase, and then diluted to the same 
concentration as above with Tyrode’s solution. HSYA in 
Tyrode’s solution was used as the control.
The everted gut sacs were prepared using the jejuna 
from male Wistar rats. After fasting overnight, the rats were 
sacrificed under ether anesthesia, and the intestine extending 
from the pyloric end to the ileocecal junction was carefully 
excised. Fat and mesenteric attachments were removed. 
The separated segment was immediately chilled, and slowly 
flushed with ice-cold saline 0.9% using a syringe fitted with 
a blunt needle. Everted sacs 6 cm in length were made from 
the jejunum without Peyer’s patches according to the method 
described by Wilson and Wiseman.20 The distal end of the sac 
was tied with a ligature. Another ligature was placed loosely 
around the proximal end.
The everted sacs were incubated in Tyrode’s buffer 
(37°C) saturated with 95% O2 and 5% CO2 in different donor 
solutions, and filled with 0.5 mL of blank Tyrode’s buffer. 
At predetermined intervals (15, 30, 45, and 60 minutes), 
0.5 mL samples were taken from the internal medium, and 
0.5 mL of fresh Tyrode’s buffer (37°C) was then added to 
the sacs. The samples were diluted by methanol followed by 
centrifugation, and 50 µL of supernatant was then injected 
into a high-pressure liquid chromatography (HPLC) column 
to determine the concentration of HSYA. Cumulative trans-
port (CT) was calculated by the following equation:
CT g/cm
2 ()
()
()
µ=
Qg
Ac m
µ
2
where Q is the amount of cumulative drug molecule transport 
and A is the area of the intestinal sac.
Intestinal tissue activity was measured for the duration 
of the experiment using the lactate dehydrogenase method.21 
Liberation of cytosolic lactate dehydrogenase was determined 
in the incubation media in the absence and presence of the for-
mulations using a lactate dehydrogenase diagnostic cassette.
hPLc analysis of samples
Chromatographic analysis was performed as previously 
described,22 with some modifications. A Shim-pack CLC-
ODS C18 (150 × 4.6 mm, internal diameter, 5 µm) HPLC col-
umn (Shimadzu, Kyoto, Japan) was used. The mobile phase 
comprised a potassium dihydrogen phosphate 0.022 mol/L 
solution, adjusted to pH 3.0 with phosphoric acid for pump 
A and acetonitrile 90% (v/v) for pump B. The total flow 
rate was 1 mL/min. A gradient elution for A:B (0 minutes, 
83:17; 7 minutes, 75:25; 7.01 minutes, stop) was used for 
the transport study. A gradient elution for A:B (0 minutes, 
90:10; 20 minutes, 74:26; 20.01 minutes, stop) was used for 
the in vivo study. The column oven temperature was 30°C. 
Detection was performed at a wavelength of 403 nm.
statistical analysis
All values are expressed as the mean ± standard deviation. 
One-way analysis of variance and Student’s t-test were used 
to analyze the results, with P , 0.05 accepted as the minimum 
level of significance.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Results
Optimization of microemulsion 
composition
A typical pseudoternary phase diagram of PG, Cremophor 
RH40/ethanol (w/w, 2:1) and water was constructed. As 
shown in Figure 1, a clear and transparent microemulsion 
was identified in the microemulsion zone. The optimal micro-
emulsion was selected from this area. w/o microemulsion 
composed of 30% PG, 46% Cremophor RH40/ethanol, and 
24% water is represented by a black triangle. The HSYA 
drug loading was 3.12 mg/g.
Properties of microemulsion in vitro
The electrical conductivity, viscosity, particle size, polydis-
persity, and zeta potential of the diluted w/o microemulsion 
are summarized in Table 1. The electrical conductivity of the 
microemulsion was 38.0 µS/cm, viscosity was 567.7 ± 5.3 cP, 
diluted particle size was about 144.2 nm, and polydispersity 
was approximately 0.6. However, the zeta potential of the 
diluted microemulsion was positive (24.6 ± 1.5 mV).
Oral bioavailability in bile duct-ligated  
and non-ligated rats
The HSYA plasma concentration-time (AUC) profiles after 
intraduodenal administration of microemulsion to bile duct-
nonligated rats, bile duct-ligated rats, and the control solu-
tion are shown in Figure 2, and the main   pharmacokinetic 
parameters are listed in Table 2. The time to peak plasma 
concentration and AUC0–∞ values for HSYA after intraduo-
denal administration of the microemulsion to bile duct-
nonligated rats were significantly higher than that for bile 
duct-ligated rats (P , 0.01). The relative bioavailability 
after intraduodenal administration of microemulsion to bile 
duct-nonligated and bile duct-ligated rats was 1937% and 
181%, respectively. These results show that the enhanced 
absorption ability of the microemulsion was significantly 
affected by secretion of bile.
Lipolysis of w/o microemulsion in vitro
Consumption of NaOH during the study, reflecting the extent 
of lipolysis, is shown in Figure 3. The values presented 
have been corrected by subtracting the amount of NaOH 
consumed when the experiment was carried out without any 
formulation present. After lipolysis, the microemulsion was 
clear and transparent. The mean particle size after lipolysis 
was 53.3 nm.
hsYA transport from microemulsion 
using everted gut sacs
Figure 4 shows the time profiles for cumulative intestinal 
permeation of HSYA for the diluted microemulsion, digested 
microemulsion, and control solution. Cumulative intestinal 
HSYA permeation of the diluted microemulsion was not 
significantly different from that of the control   solution. 
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Figure 1 Pseudoternary phase diagram of the system. Clear and transparent microemulsions were formed in the W/O area. Oil was PG and emulsifier was mixture of 
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  However, at 60 minutes, cumulative intestinal HSYA 
  permeation of the digested microemulsion was 5.56-fold 
higher than that of the diluted microemulsion.
Discussion
A microemulsion is a thermodynamically stable, clear, 
transparent system and shows a broad range of structures. 
Depending on the spontaneous curvature and flexibility of the 
surfactant monolayer, bicontinuous microemulsion and liquid 
crystals appear during formation of a microemulsion.23 In our 
research, in order to achieve the optimal water content, formu-
lations with higher viscosity and electrical conductivity were 
selected, which could be near to the structure of bicontinuous 
microemulsion. The size and zeta potential of the diluted 
microemulsion were determined to characterize its properties 
after entering the gastrointestinal tract via oral administration. 
The results show that the size of the microemulsion was small, 
while the zeta potential was positive. The high positive charge 
may contribute to its high intestinal absorption.24 The w/o 
microemulsion could be transformed to a o/w emulsion or a 
w/o/w multiemulsion after it is diluted.
Microemulsion systems with nonionic surfactants, 
good biological acceptance, and emulsifying ability are 
used   extensively.25 Microemulsions have been widely used 
in improving the bioavailability of insoluble drugs26 and 
proteins.7 In our study, the w/o microemulsion significantly 
increased the oral bioavailability of HSYA, a BCS III drug. We 
postulate there are two reasons for the absorption-enhancing 
effect of microemulsions. Firstly, the lipids and surfactants in 
the microemulsion can increase cell membrane fluidity and 
open the tight junctions between cells to improve the perme-
ability of hydrophilic drug molecules.27,28 Secondly, because 
of intercalation of the digestive products of exogenous lipids 
into the intestinal bile salt-endogenous phospholipids mixed 
micelles, the amount of HSYA partitioned into the micelles 
increases, leading to an increase in the solubilization capacity 
of the gastrointestinal tract. Furthermore, our study demon-
strated the solubility of HSYA in a mixture of medium-chain 
fatty acids and propylene glycol (digestive products of PG, 
2423.26 µg/mg). Therefore, when microemulsion is applied, 
HSYA could be dissolved in mixed micelles formed by 
enzymatic products of oil, bile salts, and phospholipids, and 
then directly enter the blood circulation by vesicle-mediated 
uptake or collision transfer.5,29,30
Lipid-based formulations are digested by pancreatic 
lipase, and the rate and extent of lipolysis greatly affects the 
oral bioavailability of poorly soluble drugs.31 After digestion, 
triglycerides are converted to diglycerides, monoglycerides, 
and fatty acids,5 and, similarly, propylene glycol diesters are 
converted to propylene glycol monoesters and fatty acids. It 
has been found that fatty acids can increase the permeability 
of poorly absorbed drugs.32 However, our study showed 
that the oral bioavailability in bile duct-nonligated rats was 
higher than that in the bile duct-ligated rats. Bile salts and 
Table 1 In vitro properties of the w/o microemulsion and diluted 
microemulsion
W/O microemulsion Diluted microemulsion
σ (μS/cm) η (cP) Size (nm) Polydispersity Zeta  
potential   
(mV)
38.0 ± 2.5 567.7 ± 5.3 144.2 ± 10.5 0.60 ± 0.11 24.6 ± 1.5
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Figure  2  Plasma  concentration-time  profiles  of  HSYA  after  intraduodenal  (id) 
administration of microemulsion to bile duct non-ligated rats (), bile duct ligated 
rats () and id of control solution () (n = 6).
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Figure 3 The percent of lipolysis-time profile of the microemulsion.
Table 2 Pharmacokinetics parameters of hsYA after intraduodenal 
(id) administration of w/o microemulsion to bile duct nonligated 
rats, bile duct ligated rats and id of control solution (n = 6)
Nonligated Ligated Control
cmax (µg/ml) 5.90 ± 1.59**,## 0.49 ± 0.25 0.35 ± 0.18
MrT (min) 166.88 ± 16.85** 150.98 ± 16.46** 81.44 ± 13.66
AUc0–∞ 
(µg/ml*min)
980.55 ± 317.55**,##   91.62 ± 38.67* 50.63 ± 16.68
Frel (%) 1937 181 100
Notes: *P , 0.05 compared with control; **P , 0.01 compared with control; 
##P , 0.01 Non-ligated group compared with ligated group.
Abbreviations: MrT, mean retention time; Frel, relative bioavailability.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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pancreatic lipase were secreted by the bile duct, indicating 
that digestion of the microemulsion is also important for 
enhanced absorption of hydrophilic drugs. In addition, the 
particle size in the digested microemulsion was very small 
(53.3 nm), which was also beneficial for drug absorption. 
Importantly, most studies have suggested that the best 
absorption enhancing effect appears when drug molecules 
and enhancers arrive at the absorption sites at the same time.33 
After lipolysis, the microemulsion was still uniform, even 
after centrifugation at 12,000 g. Therefore, the HSYA and 
digestive products can arrive simultaneously at the   absorption 
sites after digestion.
In order to illustrate further the mechanism of the enhanc-
ing effect of microemulsions, the everted gut sac model 
was used to study the permeability of the microemulsion 
and the digested microemulsion. The everted gut sac is a 
popular model for the investigation of intestinal permeability. 
Through pre-experiments, a 20-fold diluted microemulsion 
was selected as the donor solution to ensure activity of the 
intestinal gut sac, with activity detected using the lactate 
dehydrogenase method.21 The results demonstrated that the 
permeability of the diluted microemulsion was similar to 
that of the control solution, while the permeability of the 
digested microemulsion was far higher than that of the control 
  solution. This again suggests that the digested microemulsion 
can enhance absorption more effectively.
Conclusion
In conclusion, HSYA could be effectively incorporated into a 
microemulsion system consisting of PG, Cremophor RH40/
ethanol, and water. The physicochemical characteristics of 
the microemulsion have been described. The microemulsion 
can markedly improve the oral bioavailability of HSYA. 
  Furthermore, digestion of the microemulsion by pancreatic 
lipase enhances the oral bioavailability of water-soluble 
drugs.
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